Male Breast Cancer Terminated Phase 2 Trials for Vorinostat (DB02546)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00132002Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast CancerTreatment